

**Amendments to the Claims:**

The following listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1. (Original) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. (Original) The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

3-10. (Cancelled)

11. (Original) An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. (Cancelled)

13. (Original) An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14-16. (Cancelled)

17. (Previously presented) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

18. (Original) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. (Original) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. (Original) A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. (Cancelled)

22. (Original) A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

23. (Original) The product produced by the method of claim 20.

24. (Previously presented) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.

25. (Previously presented) An isolated protein comprising amino acid residues 22 to 85 of SEQ ID NO:52.

26. (Previously presented) The isolated protein of 25 which comprises amino acid residues 2 to 85 of SEQ ID NO:52.

27. (Previously presented) The isolated protein of claim 25 which comprises amino acid residues 1 to 85 of SEQ ID NO:52.

28. (Previously presented) The protein of claim 25 which further comprises a heterologous polypeptide sequence.

29. (Previously presented) A composition comprising the protein of claim 25 and a carrier.

30. (Previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 25 by a cell; and
- (b) recovering said protein.

31. (Previously presented) An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HCDBP36 cDNA contained in ATCC Deposit No. PTA-499.

32. (Previously presented) The isolated protein of claim 31 which comprises the amino acid sequence of the complete polypeptide encoded by the HCDBP36 cDNA contained in ATCC Deposit No. PTA-499, excepting the N-terminal methionine.

33. (Previously presented) The isolated protein of claim 31 which comprises the amino acid sequence of the complete polypeptide encoded by the HCDBP36 cDNA contained in ATCC Deposit No. PTA-499.

34. (Previously presented) The protein of claim 31 which further comprises a heterologous polypeptide sequence.

35. (Previously presented) A composition comprising the protein of claim 31 and a carrier.

36. (Previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 31 by a cell; and
- (b) recovering said protein.

37. (Previously presented) An isolated protein consisting of at least 30 contiguous amino acid residues of amino acid residues 22 to 85 of SEQ ID NO:52.

38. (Previously presented) The isolated protein of claim 37 which consists of at least 50 contiguous amino acid residues of amino acid residues 22 to 85 of SEQ ID NO:52.

39. (Previously presented) The protein of claim 37 which further comprises a heterologous polypeptide sequence.

40. (Previously presented) A composition comprising the protein of claim 37 and a carrier.

41. (Previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 37 by a cell; and
- (b) recovering said protein.

42. (Previously presented) An isolated protein consisting of at least 30 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HCDBP36 cDNA contained in ATCC Deposit No. PTA-499.

43. (Previously presented) The isolated protein of claim 42 which consists of at least 50 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HCDBP36 cDNA contained in ATCC Deposit No. PTA-499.

44. (Previously presented) The protein of claim 42 which further comprises a heterologous polypeptide sequence.

45. (Previously presented) A composition comprising the protein of claim 42 and carrier.

46. (Previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 42 by a cell; and
- (b) recovering said protein.